Abridge Unicorn Score: 79/100
Pittsburgh, United StatesAbridge is an AI-powered platform that transforms patient-clinician conversations into structured clinical notes, aiming to reduce administrative burden and enhance understanding in healthcare. The platform serves health systems, payers, and life sciences organizations by providing an intelligence layer for every moment of care, leveraging purpose-built AI for medical dialogues.
Valuation track record
- First screened
- Jul 23, 2026
- Entry valuation
- $5.3B
- Current valuation
- $5.3B
Latest valuation verified from Live re-screening on Jul 23, 2026. Updated quarterly from public funding announcements.
Founders
Shiv Rao, MD
CEO, Co-Founder
Zachary Lipton, PhD
Co-Founder, Chief Scientist
Get the full Abridge report
Founders deep-dive, traction signals, market thesis, red flags, scoring breakdown and an audio summary, delivered to your inbox.
Frequently asked
What is Abridge's unicorn score?
Abridge has a Unicorn Screener score of 79/100, classified as "High Potential". Recommended action: buy.
What is Abridge's current valuation?
Abridge's most recently verified valuation is $5.3B, last checked on Jul 23, 2026 (source: Live re-screening).
What sector is Abridge in?
Abridge operates in the HealthTech sector and is headquartered in Pittsburgh, United States.
When was Abridge first screened?
Abridge was first screened by Unicorn Screener on Jul 23, 2026, with an entry valuation of $5.3B.